Stockscreener 앱 받기
458.99
1.28%
5.82
시간 외 거래:
453.20
-5.79
-1.26%
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market - MarketWatch
Vertex Pharma (NASDAQ: VRTX) notice: 4,062 shares proposed for resale on 06/15/2026 - Stock Titan
Vertex Pharma Stock (US92532F1003): Wall Street Analysts Lift Targets After VX-548 Progress - AD HOC NEWS
Vertex Pharma Stock (US92532F1003): Analyst sentiment and ownership moves keep VRTX in focus - AD HOC NEWS
Is It Time to Buy This Turnaround Pharma Stock? - NAI500
Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo - The Globe and Mail
Swiss National Bank Reduces Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Meiji Yasuda America Inc Invests $1.91 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Aviva PLC Buys 11,322 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Extends Pediatric Pipeline As Shares Trade Below Consensus Targets - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance Singapore
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now? - Insider Monkey
Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders - Benzinga
Goldman Sachs Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $641 - Moomoo
Vertex CASGEVY pediatric data shows 100% success in CRISPR trials - grafa.com
Zions Bancorporation National Association UT Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Reports Positive Data for Casgevy in Pediatrics - GuruFocus
Illinois Municipal Retirement Fund Reduces Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
LPL Financial LLC Has $125.53 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Fulcrum shrinks headcount 85% - Fierce Biotech
MFS Blended Research Core Equity Portfolio's Vertex Pharmaceuticals Inc(VRTX) Holding History - GuruFocus
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals stock (US92532F1003): Insider sale draws attention amid strong biotech pipeli - AD HOC NEWS
VRTX: Pipeline momentum in CF, pain, and kidney disease drives innovation-led growth outlook - TradingView
VRTX: Expanding CF, pain, and renal franchises with robust late-stage pipeline and innovation focus - TradingView
Vertex Pharma stock (US92532F1003): focus on cystic fibrosis growth and pipeline potential - AD HOC NEWS
Motley Fool Asset Management LLC Has $10.70 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Motley Fool Wealth Management LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Franklin Resources Inc. Increases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Deutsche Bank AG Has $801.94 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 1,745 Shares - MarketBeat
Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing - marketscreener.com
Vertex Pharmaceuticals (VRTX) EVP and CMO sells 1,745 shares in planned trade - Stock Titan
Can Vertex Pharmaceuticals Deepen Its Cystic Fibrosis Edge? - Kalkine Media
O Shaughnessy Asset Management LLC Buys 11,564 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Cerity Partners LLC - MarketBeat
Kyverna vs. Vertex: Clinical-Stage Risk vs. Cash-Flow Stability in Biotech InvestingNews and Statistics - IndexBox
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool
Membranous Nephropathy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Roche, BeOne Medicines, Biogen, Vertex Pharma, AstraZeneca, Alexion Pharma, Climb Bio - Barchart.com
Vertex Pharmaceuticals (VRTX) Stock Analysis: Uncovering A 22.80% Potential Upside - DirectorsTalk Interviews
News | Not built for eternity: Design technique looks to avoid permanence - CoStar
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference - BioSpace
WINTON GROUP Ltd Purchases New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
ING Groep NV Has $36.78 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Clearbridge Investments LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX is Capital World Investors' 10th Largest Position - MarketBeat
Capital International Investors Increases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Capital International Sarl - MarketBeat
Capital International Inc. CA Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Capital Group Investment Management PTE. LTD. Sells 5,421 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo - The Globe and Mail
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by TD Asset Management Inc - MarketBeat
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Mixed Recent Returns And Long Term Shareholder Gains - Yahoo Finance
FDA accepts Vertex's BLA for povetacicept in IgA nephropathy - MSN
VRTX Stock Quote Price and Forecast - CNN
Vertex Pharmaceuticals (VRTX) Reveals Promising Cystic Fibrosis Treatment Data - GuruFocus
Carmen R. Bozic sells shares at VRTX (NASDAQ: VRTX) - Stock Titan
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $550 - Moomoo
Ixlayer rolls out digital acute pain management platform in collaboration with Vertex Pharmaceuticals - Fierce Healthcare
Harvest Fund Management Co. Ltd Buys 3,527 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities - NAI500
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Sustained momentum drives Vertex Pharmaceuticals stock higher despite signs of overbought conditions - Traders Union
RBC Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $543 - Moomoo
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth - AOL.com
The Best Stocks to Invest $500 in Right Now - AOL.com
1.11%
1.57%
자본화:
|
볼륨(24시간):